2025
Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab
Bewersdorf J, Hasle V, Shallis R, Thompson E, de Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox B, Zeidan A. Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. Therapeutic Advances In Hematology 2025, 16: 20406207251347344. PMID: 40546817, PMCID: PMC12182606, DOI: 10.1177/20406207251347344.Peer-Reviewed Original ResearchThis study investigates the immune landscape of RNA splicing factor-mutant AML and MDS, showing no survival benefit from adding durvalumab to azacitidine treatment.Small Cell Lung Cancer
Kim S, Park H, Chiang A. Small Cell Lung Cancer. JAMA 2025, 333: 1906-1917. PMID: 40163214, DOI: 10.1001/jama.2025.0560.Peer-Reviewed Original ResearchThis study investigates the treatment advancements for small cell lung cancer, showing that combining chemotherapy, radiotherapy, and immunotherapy improves survival rates, highlighting the importance of early diagnosis and tailored therapy.Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer. JAMA Network Open 2025, 8: e2514519. PMID: 40493365, PMCID: PMC12152704, DOI: 10.1001/jamanetworkopen.2025.14519.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerEGFR variationPD-L1ALK rearrangementCell lung cancerDriver alterationsMedical costsLung cancerCohort studyProgrammed cell death 1 ligand 1Cell death 1 ligand 1Biomarker statusMedian overall survivalRetrospective cohort studyLower medical costsOverall survivalTargeted therapyNon-smallPatient cohortMonthly medical costsFollow-upStudy cohortBiomarker testingAssociated with higher costsLong-term Efficacy and Safety of Lifileucel Tumor-infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Melanoma: A 5-year Analysis of the C-144-01 Study.
Medina T, Chesney J, Kluger H, Hamid O, Whitman E, Cusnir M, Thomas S, Wermke M, Domingo-Musibay E, Phan G, Kirkwood J, Larkin J, Weber J, Graf Finckenstein F, Chou J, Gastman B, Wu X, Fiaz R, Sarnaik A, Curti B, Kim K, Daniels G, Wilson M, Lee S, Puzanov I, Harker-Murray A, Logan T, Simon J, Thomas I, Schuler-Thurner B, Moritz R, Hassel J, Grigoliet G, Arance A, Rubio B, Rodriguez J, Berrocal A, de Sanmamed M, Arkenau H, Evans T, Corrie P, Dalle S, Bedane C, Olah J, Orcurto A. Long-term Efficacy and Safety of Lifileucel Tumor-infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Melanoma: A 5-year Analysis of the C-144-01 Study. Journal Of Clinical Oncology 2025, 101200jco2500765. PMID: 40454684, DOI: 10.1200/jco-25-00765.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesOverall survivalLong-term efficacyCell therapyMedian duration of responseLow tumor burdenMedian overall survivalDuration of responseTumor burden reductionLong-term safety concernsBRAF/MEK inhibitorsAdvanced melanomaBrain metastasesImmune checkpointsTumor burdenMedian durationSafety profileAdverse eventsTreatment optionsInterleukin-2Follow-upLong-term benefitsOverall populationPatientsCutoff dateFirst-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAF V600E -mutated metastatic non-small cell lung cancer: The FRONT-BRAF study.
Di Federico A, Wang K, Chen M, Barsouk A, Pagliaro A, Chen L, Ogliari F, Stockhammer P, Thawani R, Raslan S, Gariazzo E, Fusco F, Hambelton G, Citarella F, Meyer D, Corassa M, Langer C, Offin M, Negrao M, Ricciuti B. First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAF V600E -mutated metastatic non-small cell lung cancer: The FRONT-BRAF study. Journal Of Clinical Oncology 2025, 43: 8574-8574. DOI: 10.1200/jco.2025.43.16_suppl.8574.Peer-Reviewed Original ResearchTP53 co-mutationsTumor proportion scoreShorter mPFSCo-mutationsBRAF V600EMEK inhibitorsPD-L1 tumor proportion scoreMetastatic non-small cell lung cancerNon-small cell lung cancerHistory of tobacco smokingFirst-line immunotherapyMedian overall survivalSubgroups of ptsTreated with BRAFProgression-free survivalRate of adverse eventsWild-type TP53Cell lung cancerHistory of smokingTobacco smoking historyScore-matched cohortWild-type IDH1PD-L1Brain metastasesLine therapyEfficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study.
Daver N, Kontro M, Rimpiläinen J, Pyörälä M, Siitonen T, Myllymäki M, Zeidner J, Witherall R, Searle E, Bono P, Berns D, Aakko S, Hollmen M, Zeidan A, Stein A. Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study. Journal Of Clinical Oncology 2025, 43: 6513-6513. DOI: 10.1200/jco.2025.43.16_suppl.6513.Peer-Reviewed Original ResearchDose-limiting toxicityMedian overall survivalMDS patientsOverall response rateDose escalationHR-MDSCLEVER-1Bone marrowRevised International Prognostic Scoring SystemDose-limiting toxicity periodMedian overall survival estimatesInternational Prognostic Scoring SystemNo dose limiting toxicitiesTreatment-emergent adverse eventsSimon 2-stage designBayesian optimal intervalBM immune microenvironmentRegimen of azacitidinePhase 1/2 studyPrimary refractory diseaseVascular endothelial receptor-1Prognostic scoring systemSafety follow-upOverall survival estimatesHigher-riskShould we treat TP53-mutated high-risk myeloid neoplasms in older patients?
Badar T, E.l. Kettani M, Shah K, Jamy O, Shallis R, Diebold K, Coltoff A, Goldberg A, Patel A, Bewersdorf J, Foucar C, Abaza Y, Palmisiano N, DuVall A, Kota V, Zeidan A, Atallah E, Litzow M. Should we treat TP53-mutated high-risk myeloid neoplasms in older patients? Journal Of Clinical Oncology 2025, 43: 6538-6538. DOI: 10.1200/jco.2025.43.16_suppl.6538.Peer-Reviewed Original ResearchMedian overall survivalHigh-risk myeloid neoplasmsAllo-HCTDuration of responseTP53-MTHypomethylating agentsVariant allele frequencyOlder ptsMyeloid neoplasmsECOG-PSHR-MDSEastern Cooperative Oncology Group performance statusMedian duration of responseTP53 variant allele frequencyAllogeneic stem cell transplantationECOG-PS 0De novo AMLLong-term remissionStem cell transplantationLow-intensity therapyMulticenter observational studyProportion of ptsDisease-directed therapyMulti-center studyMPN-BPPhase 2 trial of dual EGFR inhibition with cetuximab and afatinib in patients with recurrent/metastatic head and neck squamous cell cancers (HNSCC).
Bhatia A, Wei W, Chiorazzi M, Deshpande H, Reynolds J, Gehan D, Tara H, Newton B, Verma A, Sayed Z, Roche A, Mehra S, Judson B, Yarbrough W, Burtness B. Phase 2 trial of dual EGFR inhibition with cetuximab and afatinib in patients with recurrent/metastatic head and neck squamous cell cancers (HNSCC). Journal Of Clinical Oncology 2025, 43: 6023-6023. DOI: 10.1200/jco.2025.43.16_suppl.6023.Peer-Reviewed Original ResearchHead and neck squamous cell cancerEpidermal growth factor receptorMedian overall survivalCombination of cetuximabAdverse eventsHuman epidermal growth factor receptor (HER)-2Recurrent/metastatic head and neck squamous cell cancerRefractory to platinum-based chemotherapyEpidermal growth factor receptor targetEpidermal growth factor receptor inhibitionSingle-arm phase II trialPhosphorylated epidermal growth factor receptorCommonest adverse eventsP16+ diseaseProgression-free survivalImmune checkpoint therapyP16-positive tumorsPlatinum-based chemotherapyPrimary tumor locationPhase 2 trialPhase II trialSquamous cell cancerPost-treatment biopsiesTrials of chemotherapyEGFR inhibitor treatmentRadiation toxicity and survival in patients with interstitial lung disease and non-small cell lung cancer: A case control study
Justet A, Jackson L, Bardon M, Lerouge D, Césaire M, Loiseau C, Bergot E, Christy F, Thariat J. Radiation toxicity and survival in patients with interstitial lung disease and non-small cell lung cancer: A case control study. Cancer/Radiothérapie 2025, 29: 104622. PMID: 40311519, DOI: 10.1016/j.canrad.2025.104622.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseNon-small cell lung cancerProgression-free survivalCell lung cancerOverall survivalLung diseaseCase-control studyLung cancerCentral reviewOligometastatic non-small cell lung cancerMedian progression-free survivalCase-control study of patientsPrevalence of interstitial lung diseaseConsecutive lung cancer patientsIntensity-modulated radiotherapyStereotactic body radiotherapyMedian overall survivalThree-dimensional radiotherapyScore of fibrosisPrognosis of patientsGround-glass patternInterstitial pulmonary fibrosisStudy of patientsLung cancer patientsCancer treatment characteristicsEpigenetic therapy sensitizes anti–PD-1 refractory head and neck cancers to immunotherapy rechallenge
Qin T, Mattox A, Campbell J, Park J, Shin K, Li S, Sadow P, Faquin W, Micevic G, Daniels A, Haddad R, Garris C, Pittet M, Mempel T, ONeill A, Sartor M, Pai S. Epigenetic therapy sensitizes anti–PD-1 refractory head and neck cancers to immunotherapy rechallenge. Journal Of Clinical Investigation 2025, 135: e181671. PMID: 40091844, PMCID: PMC11910227, DOI: 10.1172/jci181671.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsAzacitidineB7-H1 AntigenEpigenesis, GeneticFemaleHead and Neck NeoplasmsHumansImmune Checkpoint InhibitorsImmunotherapyMaleMiddle AgedProgrammed Cell Death 1 ReceptorSquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentConceptsHead and neck squamous cell carcinomaTumor microenvironmentProlonged OSOverall survivalIFN-gCD8+ T cell infiltrationCD4+ T regulatory cellsOn-treatment tumor biopsiesNeck squamous cell carcinomaSystemic host immune responseBackgroundImmune checkpoint blockadeMetastatic (R/MMedian overall survivalPD-L1 expressionT cell infiltrationLocal tumor microenvironmentT regulatory cellsSquamous cell carcinomaBiologically Effective DosePhase 1b clinical trialHost immune responseCheckpoint blockadeOS ratesPD-L1Tumor biopsiesPhase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases
Weiss S, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani N, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger H. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal Of Clinical Oncology 2025, 43: 1685-1694. PMID: 40048689, PMCID: PMC12058415, DOI: 10.1200/jco-24-02219.Peer-Reviewed Original ResearchMelanoma brain metastasesOverall survivalBrain metastasesAnti-vascular endothelial growth factor therapyMedian intracranial progression-free survivalFour-year OS ratesIntracranial progression-free survivalResponse rateCirculating angiopoietin-2Median overall survivalTrial of pembrolizumabYears of pembrolizumabDose of bevacizumabProgression-free survivalPhase II trialGrowth factor therapyAdverse event ratesAssociated with responseOS ratesPD-1Radiation necrosisLocal therapyOn-therapyMetastatic tumorsFactor therapyA plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML
Garcia-Manero G, McCloskey J, Griffiths E, Yee K, Zeidan A, Al-Kali A, Deeg H, Sabloff M, Keating M, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, DeZern A, O'Connell C, Roboz G, Busque L, Buckstein R, Amin H, Leber B, Shastri A, Oganesian A, Keer H, Azab M, Savona M. A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML. Future Oncology 2025, 21: 929-941. PMID: 40051275, PMCID: PMC11938952, DOI: 10.1080/14796694.2025.2468578.Peer-Reviewed Original ResearchChronic myelomonocytic leukemiaAcute myeloid leukemiaIntravenous decitabineMyelodysplastic syndromeDEC-COral decitabineSide effectsRed blood cell transfusionPhase 3 clinical trialsMedian overall survivalTreatment-related deathsBlood cell transfusionDays of treatmentTransfusion independenceOverall survivalCell transfusionDecitabine groupMyelomonocytic leukemiaMyeloid leukemiaOral medicineDecitabineQuality of lifeReceiving treatmentTaking treatmentCedazuridineEfficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
Qi C, Shen L, Andre T, Chung H, Cannon T, Garralda E, Italiano A, Rieke D, Liu T, Burcoveanu D, Neu N, Mussi C, Xu R, Hong D, Drilon A, Berlin J. Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. European Journal Of Cancer 2025, 220: 115338. PMID: 40068370, DOI: 10.1016/j.ejca.2025.115338.Peer-Reviewed Original ResearchTreatment-related adverse eventsSafety of larotrectinibMicrosatellite instability-highGI cancersMedian duration of responseNext-generation sequencing testMedian overall survivalProgression-free survivalDuration of responseNTRK gene fusionsOverall response rateFirst-in-classOverall survivalMedian durationTRK inhibitorsSolid tumorsTumor typesAdverse eventsExtended survivalLarotrectinibGastrointestinal cancerPatientsHepatic cancerResponse rateCancerA Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children
McGovern S, Johnson J, Luo D, Nguyen K, McAleer M, Paulino A, Grosshans D, Baxter P, Zaky W, Thall P, Mahajan A. A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children. International Journal Of Radiation Oncology • Biology • Physics 2025, 121: e13-e14. DOI: 10.1016/j.ijrobp.2024.11.049.Peer-Reviewed Original ResearchDose-volume constraintsSymptomatic brain necrosisRecurrent brain tumorsBrain tumorsBrain necrosisPrimary endpointDose constraintsProton therapyProspective studyRecurrent pediatric brain tumorsMedian overall survivalMedian prescription doseCourse of radiationResults Median ageTreated with radiationPediatric brain tumorsPrimary brain tumorProgression of diseaseBrain reirradiationDosimetric guidelinesDose escalationPrescription doseOverall survivalMedian intervalProspective trialsEVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES
Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES. Urologic Oncology Seminars And Original Investigations 2025, 43: 43. DOI: 10.1016/j.urolonc.2024.12.109.Peer-Reviewed Original ResearchPlasmacytoid urothelial carcinomaNational Cancer DatabaseMedian overall survivalNeoadjuvant chemotherapyUrothelial carcinomaOverall survivalImpact of neoadjuvant chemotherapyResponse to current therapiesCharacterize treatment patternsPrimary treatment typeCox proportional hazards analysisSite of metastasisEvaluate clinical outcomesProportional hazards analysisBorderline statistical significancePT0 rateOS benefitHistological subtypesCancer DatabaseClinical stageClinical outcomesTreatment patternsCurrent therapiesInstitutional experiencePrimary outcomeA phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.
Sadeghi S, Callis S, Lara P, Berg S, Brown J, Bangs R, Nakagawa D, Daneshmand S, Ian Murchie Jr., Flaig T, Petrylak D, Lerner S. A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design. Journal Of Clinical Oncology 2025, 43: tps887-tps887. DOI: 10.1200/jco.2025.43.5_suppl.tps887.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaProgression-free survivalStandard of careEnfortumab vedotinOverall survivalCisplatin-ineligible metastatic urothelial carcinomaMedian progression-free survivalPhase III randomized trialStudies of eribulinMedian overall survivalPlatinum-based chemotherapyLines of therapyEndpoint of OSOne-sided alphaFGFR3 alterationsLiver metastasesSystemic therapyEligible ptsUrothelial carcinomaPrimary endpointSecondary endpointsGenitourinary cancersEribulinTreatment changesGemcitabineSurvival of patients with metastatic renal cell carcinoma with or without brain metastases.
Hurwitz M, Considine B, Hasson N, Savion Gaiger N, Nelson M, Chiang V, Kluger H, Braun D, Schoenfeld D, Sznol M, Leapman M. Survival of patients with metastatic renal cell carcinoma with or without brain metastases. Journal Of Clinical Oncology 2025, 43: 476-476. DOI: 10.1200/jco.2025.43.5_suppl.476.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsClear cell RCCRenal cell carcinomaImmune checkpoint inhibitor therapyMetastatic clear cell RCCBrain metastasesOverall survivalCell carcinomaImmune checkpoint inhibitor eraPrevalence of brain metastasesMultivariate Cox proportional hazards modelAssociated with poor survivalMedian overall survivalAssociated with poor prognosisCompare overall survivalImproved overall survivalAdverse prognostic indicatorDevelopment of BMSurvival of patientsKaplan-Meier analysisYale Cancer CenterRetrospective cohort studyCox proportional hazards modelsProportional hazards modelOlaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
Cecchini M, Pilat M, Uboha N, Azad N, Cho M, Davis E, Ahnert J, Tinoco G, Shapiro G, Khagi S, Powers B, Spencer K, Groisberg R, Drappatz J, Chen L, Das B, Bao X, Li J, Narayan A, Vu D, Patel A, Niger M, Doroshow D, Durecki D, Boerner S, Bindra R, Ivy P, Shyr D, Shyr Y, LoRusso P. Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial. Cancer 2025, 131: e35755. PMID: 39917990, PMCID: PMC11949439, DOI: 10.1002/cncr.35755.Peer-Reviewed Original ResearchConceptsProgression-free survivalHomologous recombination deficiencyClinical benefitNational Cancer InstituteIDH inhibitorsMedian progression-free survivalAccumulation of 2-hydroxyglutaratePhase 2 clinical trialIsocitrate dehydrogenase inhibitorsMedian overall survivalSingle-agent activityNovel combination therapiesEnhance patient selectionSubgroup of patientsOverall survivalOpen-labelCombination therapyIDH mutationsPatient selectionRecombination deficiencySolid tumorsTumor progressionClinical trialsOlaparibCholangiocarcinomaGlobal outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium
Han J, Koh M, Boussi L, Sorial M, McCabe S, Peng L, Singh S, Eche-Ugwu I, Gabler J, Turizo M, MacVicar C, Garg A, Disciullo A, Chopra K, Lenart A, Nwodo E, Barnes J, Koh M, Miranda E, Chiattone C, Stuver R, Horwitz S, Merrill M, Jacobsen E, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim Y, Kim J, Cho J, Eipe T, Shet T, Sridhar E, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince H, Hamouche R, Murdashvili T, Foss F, Gentilini M, Casadei B, Zinzani P, Okatani T, Yoshida N, Yoon S, Kim W, Panchoo G, Mohamed Z, Verburgh E, Alturas J, Al-Mansour M, Ford J, Cabrera M, Ku A, Bhagat G, Ma H, Sawas A, Kariya K, Iwasaki M, Bhanushali F, O’Connor O, Marchi E, Shen C, Shah D, Jain S. Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium. Blood Advances 2025, 9: 583-602. PMID: 39481087, PMCID: PMC11821408, DOI: 10.1182/bloodadvances.2024014674.Peer-Reviewed Original ResearchNK-cell lymphomasOverall survivalMature T cellsALK-ALCLNK cellsT cellsAssociated with 3-year OSTiming of second-line treatmentSuperior median overall survivalMedian overall survivalPrimary refractory diseaseProgression-free survivalInternational retrospective cohort studySecond-line treatmentEfficacy of novel drugsIdentified several independent predictorsRetrospective cohort studyR/R lymphomaExtranodal sitesPTCL-NOSIntermediate-riskCytotoxic chemotherapyHistological subtypesRefractory diseaseRelapsed lymphomaFamitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study
Ai L, Li Q, Zhang S, Dong Y, Yang M, Li J, Pan Y, Yuan Y, Yi S, Wang J, Cheng Y, Feng J, Gao S, Wang X, Qu S, Zhang X, Lu J, Xiu P, Wang S, Yang X, Yu Y, Liu T. Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study. The Innovation 2025, 6: 100745. PMID: 39872476, PMCID: PMC11763884, DOI: 10.1016/j.xinn.2024.100745.Peer-Reviewed Original ResearchProgression-free survivalDuration of responseAdvanced colorectal cancerOverall survivalColorectal cancerMedian duration of responseMedian progression-free survivalMetastatic colorectal cancer patientsTreatment-related adverse eventsMedian follow-up timeMedian overall survivalMetastatic solid tumorsPD-1 antagonistsFollow-up timeCohort of patientsAnti-angiogenic agentsColorectal cancer patientsInhibition of angiogenesisPD-1Immune checkpointsMetastatic diseaseBasket studyMedian durationPrimary endpointSystemic treatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply